Liraglutide Plus Megestrol Acetate in Endometrial Atypical Hyperplasia

Launched by XIAOJUN CHEN · Dec 23, 2020

Keywords

ClinConnect Summary

Backgrounds: High-dose progesterone (MA/MPA) or LNG-IUS is the first-line treatment for women with atypical endometrial hyperplasia (AEH) or early endometrioid cancer who want to preserve fertility. About 70-80% of them can achieve complete response (CR) with the median time of 7-8 months. Over 10% of the patients can not achieve CR and choose operation finally. By the way, long-term treatment of progesterone has many side effects. Our previous study showed that overweight (BMI≥25kg/m2) AEH patients had a significantly increased risk of progesterone treatment failure, and the time to achiev...

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • BMI (body mass index) ≥28kg/m2
• • Consent informed and signed
• • Pathologically confirmed as endometrial atypical hyperplasia
• • Have a strong desire to reproduce and ask for fertility preservation or those who insist on keeping the uterus despite no reproductive requirements
• • Have good compliance and follow-up conditions, and patients are willing to follow up in Obstetrics and Gynecology Hospital of Fudan University in time
• Exclusion Criteria:
• • Diagnosed as type 2 diabetes
• • Diabetic ketoacidosis
• • History of acute pancreatitis
• • Have a history or family history of medullary thyroid carcinoma; multiple endocrine neoplasia syndrome type 2 (MEN2)
• • Combined with severe medical disease or severely impaired liver and kidney function
• • Patients with other types of endometrial cancer or other malignant tumors of the reproductive system; patients with breast cancer or other hormone-dependent tumors that cannot be used with progesterone
• • Those who require hysterectomy or other methods other than conservative treatment with drugs
• • Deep vein thrombosis, stroke, myocardial infarction
• • Smokers (≥15 cigarettes/day)